What is Seer, Inc.'s market cap?

Seer, Inc. (SEER) has a market capitalization of $108.3M and trades on NASDAQ.

Who are Seer, Inc.'s competitors?

Seer, Inc.'s key competitors include Quantum-Si, Bio-Techne, Nautilus Biotechnology, and others. These companies compete in similar markets and product categories.

Who does Seer, Inc. partner with?

Seer, Inc.'s notable partners include Thermo Fisher Scientific, Hamilton Company, The Brigham and Women’s Hospital, and others.

What subsidiaries does Seer, Inc. have?

Seer, Inc.'s subsidiaries include PrognomiQ.

Where is Seer, Inc. headquartered?

Seer, Inc. is headquartered in United States of America and employs approximately 147 people. It has been publicly traded since 2020.

Seer, Inc.

SEER

Seer, Inc. is a life sciences technology company that provides a proprietary platform for deep, unbiased, and large-scale proteomic analysis.

Market cap

$108.31M-15.2%

Table of contents

Earnings

Q1 2026 report

May 13, 2026

Revenue$2.8MMiss by $807.0K EPS-$0.30Miss by $0.01

Read the full report

Next report

Aug 5, 2026 (In 1 week)

Revenue estimate$3.6M

EPS estimate-$0.27

Competitors

By market cap

Thermo Fisher Scientific$207.93B+13.6%

Agilent Technologies$38.9B+14.7%

TEC

Bio-Techne$11.2B+21.6%

Bruker$9.1B+37.3%

Nautilus Biotechnology, Inc.$211.0M+114%

Quanterix Corporation$172.9M-42.9%

Quantum-Si Incorporated$170.6M-52.7%

Seer, Inc.$108.3M-16.3%

By revenue growth

Agilent Technologies+9.1%

Quanterix Corporation+6.9%

Thermo Fisher Scientific+5.6%

Bruker+0.4%

TEC

Bio-Techne+0.2%

By net margin

Agilent Technologies19.55%+2.0pp

Thermo Fisher Scientific15.19%0.0pp

TEC

Bio-Techne10.89%-0.7pp

Bruker-0.608%-3.9pp

Quanterix Corporation-71.86%-36.6pp

Profile

Seer, Inc. is a life sciences technology company that provides a proprietary platform for deep, unbiased, and large-scale proteomic analysis. Its core value proposition is the Proteograph Product Suite, which leverages engineered nanoparticle technology to enable researchers to decode the complex biology of the proteome with high throughput and peptide-level resolution. The company aims to bridge the gap between genomic variation and functional biology to power AI-driven scientific discovery and precision medicine.

Competitive position

A pioneer in nanoparticle-based unbiased protein enrichment for mass spectrometry, offering a unique combination of depth, reproducibility, and population-scale throughput.

GeographiesNorth America, European Union, United Kingdom, Asia Pacific

Customer segmentsResearch laboratories, Pharmaceutical R&D, Academic researchers, Diagnostic developers

Business modelRazor-and-blade, Equipment sales, Consumable sales, Cloud-based SaaS

SuppliersMass spectrometry instrument manufacturers, Raw material suppliers for nanoparticle formulation, Third-party contract manufacturers for liquid handling hardware

CustomersGenomics and proteomics researchers, Multi-omic diagnostic developers, Population-scale biobanks, Therapeutic drug discovery teams

CountryUnited States of America

Listed2020

Employees147.0

CEOOmid C. Farokhzad

SectorHealthcare

IndustryBiotechnology

Websiteseer.bio

FilingsSEC EDGAR

Questions, answered.

What is Seer, Inc.'s market cap?: Seer, Inc. (SEER) has a market capitalization of $108.3M and trades on NASDAQ.
Who are Seer, Inc.'s competitors?: Seer, Inc.'s key competitors include Quantum-Si, Bio-Techne, Nautilus Biotechnology, and others. These companies compete in similar markets and product categories.
Who does Seer, Inc. partner with?: Seer, Inc.'s notable partners include Thermo Fisher Scientific, Hamilton Company, The Brigham and Women’s Hospital, and others.
What subsidiaries does Seer, Inc. have?: Seer, Inc.'s subsidiaries include PrognomiQ.
Where is Seer, Inc. headquartered?: Seer, Inc. is headquartered in United States of America and employs approximately 147 people. It has been publicly traded since 2020.